Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $8,501,142.40 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 386,240 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the completion of the sale, the insider owned 1,019,658 shares of the company’s stock, valued at $22,442,672.58. This trade represents a 27.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $21.80 on Friday. The stock has a 50-day simple moving average of $16.65 and a 200 day simple moving average of $16.00. The stock has a market capitalization of $3.49 billion, a P/E ratio of -66.06 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 52 week low of $9.96 and a 52 week high of $22.80.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the prior year, the company earned ($0.20) earnings per share. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Morgan Stanley raised their price target on Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a report on Thursday. BTIG Research reaffirmed a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 29th. TD Cowen raised their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.83.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds have recently added to or reduced their stakes in the stock. 1492 Capital Management LLC bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at $1,484,000. Jupiter Asset Management Ltd. grew its stake in Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after buying an additional 91,683 shares in the last quarter. Rhenman & Partners Asset Management AB increased its holdings in Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock valued at $9,825,000 after buying an additional 110,000 shares during the period. UBS Group AG increased its holdings in Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after buying an additional 257,947 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at approximately $65,942,000. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.